Edition:
United Kingdom

Akcea Therapeutics Inc (AKCA.OQ)

AKCA.OQ on NASDAQ Stock Exchange Global Select Market

29.62USD
6:33pm GMT
Change (% chg)

$-0.04 (-0.13%)
Prev Close
$29.66
Open
$29.25
Day's High
$30.40
Day's Low
$28.75
Volume
36,912
Avg. Vol
98,094
52-wk High
$40.60
52-wk Low
$15.24

Chart for

About

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense... (more)

Overall

Beta: --
Market Cap(Mil.): $1,860.50
Shares Outstanding(Mil.): 66.54
Dividend: --
Yield (%): --

Financials

  AKCA.OQ Industry Sector
P/E (TTM): -- 31.23 33.59
EPS (TTM): -4.36 -- --
ROI: -- 15.57 15.05
ROE: -- 16.94 16.62

Akcea Therapeutics genetic disease treatment gets FDA approval

Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals , which targets a rare genetic disease was approved by the U.S. Food and Drug Administration.

05 Oct 2018

Akcea Therapeutics genetic disease treatment gets FDA approval

Oct 5 Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals , which targets a rare genetic disease was approved by the U.S. Food and Drug Administration.

05 Oct 2018

Akcea Therapeutics to cut about 10 percent of workforce

Akcea Therapeutics Inc said on Thursday it planned to cut its workforce by about 10 percent after the U.S. health regulator declined to approve its Waylivra drug for treating a genetic disease that causes fat accumulation in blood.

06 Sep 2018

UPDATE 1-Akcea Therapeutics to cut about 10 pct of workforce

Sept 6 Akcea Therapeutics Inc said on Thursday it planned to cut its workforce by about 10 percent after the U.S. health regulator declined to approve its Waylivra drug for treating a genetic disease that causes fat accumulation in blood.

06 Sep 2018

Akcea Therapeutics to cut about 10 pct of workforce

Sept 6 Akcea Therapeutics Inc said on Thursday it planned to cut its workforce by about 10 percent after the U.S. health regulator declined to approve its Waylivra drug for treating a genetic disease that causes fat accumulation in blood.

06 Sep 2018

FDA declines to approve Akcea-Ionis genetic disease drug

The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease that causes fat accumulation in the blood.

27 Aug 2018

UPDATE 1-FDA declines to approve Akcea/Ionis genetic disease drug

Aug 27 The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease that causes fat accumulation in the blood.

27 Aug 2018

U.S. FDA declines to approve Akcea/Ionis genetic disease drug

Aug 27 The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease which causes fat accumulation in the blood.

27 Aug 2018

Earnings vs. Estimates